

GP RESEARCH REVIEW™

Making Education Easy

Issue 168 – 2021

In this issue:

- Hydroxychloroquine for prevention of COVID-19
- Macrolides in pregnancy and risk of major birth defects
- Statin treatment and muscle symptoms
- Azithromycin for hospital patients with COVID-19
- High-intensity strength training for knee osteoarthritis
- Time to benefit of statins for prevention of cardiovascular events
- Immunosuppression as a risk factor for COVID-19
- Fast-food outlet density and incidence of myocardial infarction
- *Curcuma longa* extract for knee osteoarthritis
- Egg consumption and risk of cardiovascular events

Abbreviations used in this issue

CI = confidence interval

COVID-19 = coronavirus disease-2019

HR = hazard ratio

PCR = polymerase-chain-reaction

RR = risk ratio

SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2



Welcome to Issue 168 of GP Research Review. Further evidence has emerged that hydroxychloroquine is ineffective in preventing the transmission of SARS-CoV-2 infection among contacts of confirmed COVID-19 patients. Furthermore, hydroxychloroquine has exhibited a treatment-related adverse event rate of 56.1%. In the Natural Health section, Dr Chris Tofield has reviewed two interesting studies, one showing the benefits of *Curcuma longa* extract for knee osteoarthritis and the other egg consumption and the risk of cardiovascular events.

I hope you enjoy this issue and I welcome your comments and feedback.

Jim

Assoc Professor Jim Reid

jimreid@researchreview.co.nz

A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19

Authors: Mitjā O et al

Summary: This Spanish open-label, cluster-randomised trial tested the effect of hydroxychloroquine (800mg followed by 400mg daily for 6 days) in the prevention SARS-CoV-2 infection among 2314 asymptomatic contacts of polymerase-chain-reaction (PCR)-confirmed COVID-19 patients (n = 672). There were no differences between treatment groups in incidence of PCR-confirmed, symptomatic COVID-19 (hydroxychloroquine 5.7%; usual-care 6.2%; RR 0.86; 95% CI 0.52-1.42), nor a difference in incidence of SARS-CoV-2 infection defined by symptoms compatible with COVID-19 or a positive PCR test regardless of symptoms (18.7% vs 17.8%). Adverse event rates were higher in hydroxychloroquine than usual-care recipients (56.1% vs 5.9%), but there were no treatment-related serious adverse events.

Comment: Another one! Not only is hydroxychloroquine useless for the treatment of COVID-19, it has a similar profile for its use in prevention. It was also spectacular in the incidence of adverse effects (56.1% vs 5.9% against the placebo group)!!!

Reference: *N Engl J Med.* 2021;384(5):417-427

[Abstract](#)

Independent commentary by Associate Professor Jim Reid

Jim Reid graduated in medicine at the University of Otago Medical School in Dunedin, New Zealand. He had previously trained as a pharmacist. He undertook postgraduate work at the University of Miami in Florida, USA. **For full bio** [CLICK HERE](#).



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)

Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).

New Patient Information Sheets to help support your NVAF and VTE patients who have been prescribed XARELTO.



Access patient sheets here: [Te Reo Māori](#), [English](#), [Samoan](#) and [Tongan](#)

NVAF = nonvalvular atrial fibrillation; **VTE** = venous thromboembolism

Xarelto® (rivaroxaban) Prescription Medicine. Oral tablets containing 10 mg, 15 mg or 20 mg rivaroxaban. **INDICATIONS:** 1) For the prevention of venous thromboembolism in elective hip and knee replacement surgery. 2) Prevention of stroke and systemic embolism in non-valvular atrial fibrillation and at least one additional risk factor. 3) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Before prescribing Xarelto® please review the Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects. The Data Sheet is available at <https://medsafe.govt.nz/profs/Datasheet/x/XareltoTab.pdf> or click [here](#). Bayer New Zealand Ltd, B:HIVE, Smales Farm, 74 Taharoto Road, Takapuna, Auckland 0622. Xarelto® is a registered trademark of the Bayer Group, Germany. PP-XAR-NZ-0130-1. TAPS NA 12618. December 2020. BY10036.





Jardiance®
(empagliflozin)

FULLY FUNDED
with Special Authority criteria*
February 1st, 2021

NEW. For your patients with type 2 diabetes†

THE POWER TO ACCOMPLISH MORE
Above and beyond glycaemic control^{1,2}

Click below to download your JARDIANCE resources

PRESCRIBING GUIDE **PATIENT BOOKLET**

Association between use of macrolides in pregnancy and risk of major birth defects: Nationwide, register based cohort study

Authors: Andersson NW et al.

Summary: This Danish register-based cohort study (n = 1,192,539; 1997-2016) assessed the relationship between the use during pregnancy of macrolide antibiotics (n = 13,019) versus phenoxymethylpenicillin (propensity matched 1:1) or no antibiotic use (propensity matched 1:4) and the risk of major birth defects. Across the matched pregnancies, there were 457 infants born with major birth defects after macrolides use (35.1 per 1000 pregnancies) versus 481 infants (37.0 per 1000 pregnancies) after penicillin use (RR 0.95; 95% CI 0.84-1.08); absolute risk difference per 1000 pregnancies of -1.8 (95% CI -6.4 to 2.7). Major birth defect risk was not increased among women using macrolides during versus recently before becoming pregnant (RR 1.00; 95% CI 0.88-1.14) or versus women who did not use any antibiotics (RR 1.05; 95% CI 0.95-1.17).

Comment: This is a very large study that demonstrates the safety of use of the macrolide antibiotics (e.g., erythromycin, roxithromycin, azithromycin) in pregnancy. This is in line with recommendations made in the New Zealand Formulary.

Reference: *BMJ.* 2021;372:n107

[Abstract](#)

Statin treatment and muscle symptoms: Series of randomised, placebo controlled n-of-1 trials

Authors: Herrett E et al.

Summary: This UK series of double-blinded trials across 50 sites examined the effect of reintroduction of statins (six 2-month treatment periods with atorvastatin 20mg daily or placebo) on muscle symptoms in 200 people who had recently stopped or were considering stopping statins because of muscle symptoms. Muscle symptoms on a visual analogue scale (0-10) were provided by 151 participants for at least one statin and one placebo period. Overall, there were no differences in muscle symptom scores between statin and placebo periods (mean difference -0.11; 95% CI -0.36 to 0.14). Withdrawal because of intolerable muscle symptoms occurred in 18 (9%) participants during a statin period and 13 (7%) participants during a placebo period. Two-thirds of those completing the trial restarted long-term statin treatment.

Comment: There is, in my experience, a strong folk law in existence, fanned by a radio talkback host, about the side effects of statins. Callers complain of dementia, tiredness, and most of all, muscle pains. While I have no doubt that for some these are very real, but in others...? This double-blind, placebo-controlled, cross-over study in statin recipients who had previously suffered from muscle pains, demonstrated that over the study periods, there was no difference in muscle symptom scores between those on 20mg atorvastatin and placebo. However, I do note that there was a higher drop-out rate among those during their statin periods. Still inconclusive...

Reference: *BMJ.* 2021;372:n135

[Abstract](#)

[†]38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).[‡]
*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. †In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. ‡The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).^{1,2}

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med.* 2015;373(22):2117-2128

JARDIANCE® empagliflozin 10mg, 25mg film coated tablets Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>
INDICATION: *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy:* When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy:* With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m² or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m² or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m²; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370



Boehringer Ingelheim (NZ) Ltd.
PO Box 76216 Manukau City,
Auckland 2241. Phone 0800 802 461



Eli Lilly and Company (NZ) Ltd.
PO Box 109197 Newmarket,
Auckland 1149. Phone 0800 505 056
NZBN 9429039560643

For more information, please go to www.medsafe.govt.nz

Consider switching your SPIRIVA Handihaler (dry powder) patients to SPIRIVA RESPIMAT Soft Mist Inhaler*^{1,2}

*Treatment decisions, including inhaler choice, should be based on individual assessment of each patient³



The same SPIRIVA you trust[†] with the easy inhalation of RespiMat^{†1,2,4-8}

[†]Over 15 years prescribing experience in New Zealand and more than 31 million patient-years of use worldwide^{2,8} [†]Targeted inspiratory flow rate is 30 L/min⁹, so only a slow, deep breath is required¹.

References: 1. SPIRIVA RespiMat Approved NZ Data Sheet, July 2019. 2. SPIRIVA Approved NZ Data Sheet, March 2019. 3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management and prevention of COPD – 2020. Available at: <https://goldcopd.org/gold-reports>. Accessed January 2020. 4. Hodder R, Price D. Int J COPD 2009;4:381–90. 5. Schürmann W et al. Treat Respir Med 2005;4:53–61. 6. Kardos P et al. Eur Respir J 2005;26(Suppl 49):338s. 7. Wachtel H et al. Pulm Ther 2017;3:19–30. 8. Halpin D et al. Int J COPD 2015;10:239–59. 9. Pitcairn G et al. J Aerosol Med 2005;18:264–72.

Before prescribing, please review the full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>

SPIRIVA® (tiotropium) 18 mcg powder for inhalation, capsules and SPIRIVA® RESPIMAT® (tiotropium) 2.5 micrograms/puff, solution for inhalation ABRIDGED PRESCRIBING INFORMATION
INDICATIONS: Long term once daily maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Reduces frequency of exacerbations, improves exercise tolerance and health-related quality of life. **DOSAGE:** SPIRIVA capsules: Inhalation of the contents of one capsule, once daily with the HandiHaler device, at the same time of day. SPIRIVA RESPIMAT: Two puffs once daily at the same time each day. Do not use more than once daily. Cartridges to be used only with RESPIMAT inhaler. **CONTRAINDICATIONS:** Hypersensitivity to atropine or its derivatives, or to any component of the product. **WARNINGS AND PRECAUTIONS:** SPIRIVA capsules and SPIRIVA RESPIMAT: Should not be used for the initial treatment of acute episodes of bronchospasm, immediate hypersensitivity reactions, narrow-angle glaucoma, prostatic hyperplasia, bladder-neck obstruction, inhalation-induced bronchospasm, moderate to severe renal impairment (CrCL ≤ 50 mL/min), pregnancy, lactation, children. SPIRIVA capsules: Avoid powder entering eyes. Contains lactose. SPIRIVA RESPIMAT: Should not be used for the relief of acute symptoms. Cardiac rhythm disorders. Avoid solution or mist entering eyes. **ADVERSE EFFECTS:** Common: Dry mouth (usually mild) Serious: glaucoma, supraventricular tachycardia, atrial fibrillation, tachycardia, bronchospasm (including inhalation-induced), gastroesophageal reflux disease, constipation, intestinal obstruction incl. ileus paralytic, hypersensitivity reactions (including immediate reactions), urinary retention, urinary tract infection. Others, see full Data Sheet. **INTERACTIONS:** Co-administration with other anticholinergic drugs. **ACTIONS:** Tiotropium is a specific antimuscarinic agent (anticholinergic), which provides significant and long-acting (24 hours) bronchodilation in patients with COPD, with no evidence of tolerance. The long duration is due to the high potency and slow receptor dissociation from the muscarinic M3 receptor. Bronchodilation is primarily a local effect (on the airways), not a systemic one. **PRESCRIPTION MEDICINE** SPIRIVA® and SPIRIVA® RESPIMAT® are fully funded – Pharmaceutical Schedule, www.pharmac.govt.nz. Prescription must be endorsed that the patient has been diagnosed as having COPD using spirometry. BOEHRINGER INGELHEIM (N.Z.) Ltd. Level 3, 2 Oysterley Way Manukau Auckland 2104. Spiriva® and RespiMat® are registered trademarks of Boehringer Ingelheim. 13 September 2018. PC-NZ-100107 TAPS PP6098



For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial

Authors: RECOVERY Collaborative Group

Summary: In the UK multicentre, randomised, controlled, open-label, adaptive platform RECOVERY trial, azithromycin 500mg once daily was tested to see if its immunomodulatory actions would benefit patients admitted to hospital with COVID-19. In total, 2582 patients received azithromycin and 5181 usual care (mean age 65.3 years; 38% women). Overall, 22% of both groups of patients died within 28 days (RR 0.97; 95% CI 0.87-1.07). There was no difference in duration of hospital stay (median 10 vs 11 days) or proportion discharged alive within 28 days (RR 1.04; 95% CI 0.98-1.10). In those not receiving invasive mechanical ventilation at baseline, there was no difference in the proportion meeting a composite endpoint of invasive mechanical ventilation or death (RR 0.95; 95% CI 0.87-1.03).

Comment: COVID-19 is dominating the medical literature at present. This time another blank on the effectiveness of use of azithromycin. It should be kept for the treatment of appropriate infection.

Reference: *Lancet*. 2021;397(10274):605–612
Abstract

Effect of high-intensity strength training on knee pain and knee joint compressive forces among adults with knee osteoarthritis: The START randomized clinical trial

Authors: Messier SP et al.

Summary: This US, single-centre, assessor-blinded randomised clinical trial compared high-intensity (n = 127) versus low-intensity (n = 126) strength training versus control (n = 124; providing attention, social interaction and health education) in patients with knee osteoarthritis. Over an 18-month follow-up, 320 patients (85%) completed the trial. Mean adjusted (sex, baseline BMI, baseline outcome values) Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) knee pain scores did not differ between the high-intensity strength training and control (5.1 vs 4.9; adjusted difference 0.2; 95% CI -0.6 to 1.1) or low-intensity groups (5.1 vs 4.4; adjusted difference 0.7; 95% CI -0.1 to 1.6). Nor did mean knee joint compressive forces differ between groups (2453 vs 2512 N; adjusted difference -58; 95% CI -282 to 165 N; 2453 vs 2475 N; adjusted difference -21; 95% CI -235 to 193 N). Non-serious adverse events occurred in 87 participants (53 high-intensity; 30 low-intensity; 4 control) and serious adverse events unrelated to the study in 13 participants (5 high-intensity; 3 low-intensity; 5 control).

Comment: There has been some enthusiasm for the use of high-intensity knee strengthening exercises for the treatment of osteoarthritis of the knee. This study looked at the effect on knee pain of high-intensity versus low-intensity exercise. The outcome was that there was no difference between the two groups as far as pain is concerned, but there was no measurement of disease outcome, especially with reference to need for future joint replacement.

Reference: *JAMA*. 2021;325(7):646–657
Abstract



**AFTER DOING THIS
FOR 40 YEARS,
SHE DOESN'T WANT
TO STOP NOW.**

**PROTECT YOUR NVAF PATIENTS WITH
REDUCED RENAL FUNCTION FROM STROKE
WITH XARELTO 15 MG ONCE A DAY.¹⁻³**

**Xarelto 15 mg once daily
APPROVED for use in patients
with NVAF* and CrCl 15-49 mL/min^{3y}**



^yUse with caution in patients with CrCl 15-29 mL/min. Contraindicated in patients with CrCl <15 mL/min.

*Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors. Please refer to Xarelto Data Sheet for a full list of indications.

CrCl = creatinine clearance; NVAF = nonvalvular atrial fibrillation

References: 1. Patel M.R. et al. *N Engl J Med.* 2011;365(10):883-91. 2. Fox K.A. et al. *Eur Heart J.* 2011;32:2387-94 3. Xarelto Data Sheet, 8 October 2020.

XARELTO® (rivaroxaban). Prescription Medicine. Oral tablets containing 2.5 mg, 10 mg, 15 mg or 20 mg rivaroxaban. **INDICATIONS:** Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE (see PRECAUTIONS for haemodynamically unstable PE patients). In combination with aspirin, for the prevention of major cardiovascular events (composite of stroke, myocardial infarction and cardiovascular death) in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD). **DOSAGE AND ADMINISTRATION:** Prevention of VTE in total hip replacement (treatment for up to 5 weeks), and total knee replacement (treatment for up to 2 weeks); 10mg once daily. Stroke prevention in atrial fibrillation, 20 mg once daily (15 mg once daily for patients with creatinine clearance 15-49 mL/min). Treatment of DVT and PE and for the prevention of recurrent DVT and PE; 15 mg tablet twice daily for the first 3 weeks followed by 20 mg tablet once daily. Following completion of six to twelve months therapy, based on an individual assessment of the risk of recurrent DVT or PE against the risk of bleeding, dose reduction to 10 mg once daily may be considered. CAD and/or PAD; 2.5 mg twice daily in combination with aspirin 100 mg once daily. Xarelto 15 mg and 20 mg tablets should be taken with food. Xarelto 2.5 mg and 10 mg tablets may be taken with or without food. Tablets may be crushed and administered orally (mixed with water or applesauce) or given through gastric tubes. See Data Sheet for full details. **CONTRAINDICATIONS:** Hypersensitivity to rivaroxaban or to any of the excipients, clinically significant active bleeding, lesions at increased risk of clinically significant bleeding and patients with spontaneous impairment of haemostasis, significant hepatic disease which is associated with coagulopathy, undergoing dialysis or severe renal impairment with a creatinine clearance < 15 mL/min, concomitant treatment with strong inhibitors of both CYP 3A4 and P-glycoprotein, pregnancy, lactation. **PRECAUTIONS:** Increased bleeding risk such as general haemorrhagic risk (see Data Sheet for list), renal impairment, hepatic impairment, surgery and interventions, spinal/epidural anaesthesia or puncture, patients with prosthetic valves (not recommended), haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy, patients with non-valvular atrial fibrillation who undergo PCI with stent placement (limited data), lactose intolerance, CAD and/or PAD; patients with haemorrhagic lacunar stroke, or ischaemic non-lacunar stroke (should not be used). **INTERACTIONS WITH OTHER MEDICINES:** Care to be taken if concomitantly used with medicines affecting haemostasis; increased risk of bleeding with concomitant administration with selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), non-steroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, other anticoagulants. Strong inhibitors of both CYP3A4 and P-gp. **ADVERSE EFFECTS:** Please refer to Data Sheet for a complete list. Common adverse reactions (≥ 1/100 to < 1/10) include post procedural, eye, GI tract and urogenital tract haemorrhage, haemoptysis, increased transaminases, gingival bleeding, constipation, diarrhoea, dyspepsia, nausea, vomiting, pyrexia, oedema peripheral, confusion, pain in extremity, gastrointestinal and abdominal pain, headache, fever, decreased general strength and energy, contusion, dizziness, epistaxis, haematoma, anaemia, renal impairment and ecchymosis, cutaneous and subcutaneous haemorrhage, hypotension, rash and pruritus. Less frequent but serious adverse reactions include: urticaria, cerebral and intracranial haemorrhage, jaundice, angioedema, allergic oedema, cholestasis, hepatitis and thrombocytopenia. **Based on DS:** 08 Oct 2020.

Xarelto 10 mg, 15 mg and 20 mg tablets are fully funded – no special authority. Xarelto 2.5mg tablets are not funded and are not marketed by Bayer in New Zealand. This medicine has risks and benefits. Before prescribing, please review Data Sheet for further information. Full Data Sheet is available from www.medsafe.govt.nz or Bayer New Zealand Limited, B:HIVE, Smales Farm, 74 Taharoto Rd, Takapuna, Auckland 0622. Telephone 0800 233 988.

PP-XAR-NZ-0097-2. TAPS NA 12204. Prepared December 2020 BY10040.

For more information, please go to www.medsafe.govt.nz

www.researchreview.co.nz

Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: A meta-analysis

Authors: Yourman LC et al.

Summary: This survival meta-analysis of statin randomised clinical trials was conducted to determine the time to benefit for prevention of a first major adverse cardiovascular event (MACE) based on 8 studies (n = 65,383; 66.3% male; mean age 55-69 years; mean length of follow-up 2-6 years). Only 1 study demonstrated a decrease in all-cause mortality with statins. Meta-analysis indicated that 2.5 (95% CI 1.7-3.4) years of statin treatment were needed to avoid 1 MACE per 100 patients. To prevent 1 MACE per 200 patients, the time to benefit was 1.3 years (95% CI 1.0-1.7), and to avoid 1 MACE per 500 patients was 0.8 years (95% CI 0.5-1.0).

Comment: This study reinforces the limited capacity of statins to primarily prevent a first MACE. This was a meta-analysis of only 8 trials conducted in primary care which included 65,000 odd patients aged between 50 and 75 years who did not have established cardiovascular disease. Statins did not provide any benefit in preventing mortality, and in addition it required the treatment of 100 participants for 2.5 years to prevent one MACE.

Reference: *JAMA Intern Med.* 2021;181(2):179-185
[Abstract](#)

Immunosuppression as a risk factor for COVID-19: A meta-analysis

Authors: Tassone D et al.

Summary: This random-effects meta-analysis examined whether immunosuppressed patients were at higher risk of COVID-19 based on 6 studies (n = 10,049). Prevalence of immunosuppression ranged from 0.126% to 1.357% in these study cohorts. The pooled analysis included 64 (0.637%) immunosuppressed patients with COVID-19. The observed-to-expected ratio of immunosuppression among patients with COVID-19 relative to the general community was 0.12 (95% CI 0.05-0.27) and did not indicate an increased risk.

Comment: COVID-19 again. Medically-induced immunosuppression is common, not only patients on all monoclonal antibodies, but also all on disease modifying antirheumatic drugs (DMARDs), and systemic steroids to name a few. It was previously accepted that these patients were at increased risk of an infection by COVID-19, but this paper, a meta-analysis involving 10,000 patients, demonstrated that they are not at increased risk of contracting the disease.

Reference: *Intern Med J.* 2021;51(2):199-205
[Abstract](#)

Independent Content: The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products. **Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. **Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits. **Research Review publications are intended for New Zealand health professionals.**

Impact of fast-food outlet density on incidence of myocardial infarction in the Hunter region

Authors: Saluja T et al.

Summary: This Australian retrospective cohort study (1996-2013) examined the role of fast-food outlet density as an environmental risk factor for myocardial infarction (MI) using data from the Hunter Cardiac and Stroke Outcomes unit in New South Wales. Fast-food outlet density per local government area was positively correlated with MI rates in both single and multivariate models adjusting for age, obesity, hyperlipidaemia, hypertension, smoking status, diabetes and socioeconomic status ($p < 0.001$). An increase of one fast-food outlet per local government area corresponded with 4.07 additional MIs per 100,000 people per year (95% CI 3.86-4.28).

Comment: This is an interesting study that looked at the relationship of fast-food outlet density (number of fast-food shops) and the incidence of MI in an area. Using MI as the sole indicator, there was a direct relationship between fast food outlet density and the rate of MI. This was apparent in both rural and metropolitan areas, and was also apparent after multivariate adjustment for cardiovascular risk factors. In a nutshell – the more fast food shops the more MI in the community!!

Reference: *Intern Med J.* 2021;51(2):243-248

[Abstract](#)

[CLICK HERE](#) to read previous issues of GP Research Review

Influenza Vaccine for Older Adults - E-Learning Module

Our latest E-Learning Module endorsed by the RNZCGP and College of Nurses is now available to complete just in time for the 2021 influenza season.

This is based on the **Research Review Product Review of MF59®-Adjuvanted Inactivated Quadrivalent Influenza Vaccine for Older Adults (Fluad Quad®)**, with expert commentary by Infectious disease expert Professor Tim Blackmore.

This review summarises data relevant to the use of the MF59-Adjuvanted inactivated quadrivalent influenza vaccine (Fluad® Quad) for the prevention of seasonal influenza in adults aged ≥65 years, against the background of a high burden of disease in older adults and factors that can reduce vaccine effectiveness.

[CLICK here](#) to read the review




GPs:
START MODULE



NURSES:
START MODULE

New Zealand COPD Guidelines

The **NZ COPD Guidelines** have been developed by the Asthma and Respiratory Foundation's (ARFNZ) working group of respiratory health experts led by Dr Stuart Jones from Middlemore Hospital and Professor Bob Hancox from the University of Otago, with the goal of improving diagnosis, and laying out clear recommendations for assessment and management of this respiratory disease.



[Download the NZ COPD Guidelines here](#)

EVIDENCE-BASED NATURAL HEALTH

by Dr Chris Tofield

Effectiveness of *Curcuma longa* extract for the treatment of symptoms and effusion-synovitis of knee osteoarthritis

Authors: Wang Z et al.

Summary: This Australian single-centre, randomised, double-blind, placebo-controlled trial examined the use of *Curcuma longa* extract for reducing knee symptoms and effusion-synovitis in 70 patients with symptomatic knee osteoarthritis and ultrasonography-defined knee effusion-synovitis. *Curcuma longa* extract improved visual analogue scale pain score versus placebo by -9.1 mm (95% CI -17.8 to -0.4 mm; $p = 0.039$), but had no effect on effusion-synovitis volume (3.2 mL; 95% CI -0.3 to 6.8). The extract also improved WOMAC knee pain (-47.2 mm; 95% CI -81.2 to -13.2 mm; $p = 0.006$), but not lateral femoral cartilage T2 relaxation time (-0.4 ms; 95% CI -1.1 to 0.3). Adverse event incidences did not differ between extract ($n = 14$; 39%) and placebo ($n = 18$; 53%) recipients.

Comment: Curcumin is a constituent of turmeric, which in turns comes from the root of the *Curcuma longa* plant in the ginger family. Most of you will be aware of the various anti-inflammatory and antioxidant properties of curcumin, though we're still needing studies in humans to demonstrate effects on clinical outcomes. Enter this small Tasmanian study showing some improvements in knee pain in osteoarthritis, a first step in the right direction.

Reference: *Ann Intern Med.* 2020;173(11):861-869

[Abstract](#)

Association between egg consumption and risk of cardiovascular outcomes: A systematic review and meta-analysis

Authors: Krittanawong C et al.

Summary: This meta-analysis examined the relationship between egg consumption and overall cardiovascular disease events based on 23 prospective studies ($n = 1,415,839$) with a median follow-up of 12.28 years. In total, there were 123,660 cases, and 157,324 cardiovascular disease events included in the analysis. Consumption of more than 1 egg per day versus no or 1 egg per day, was not associated with a change in risk of overall cardiovascular disease events (HR 0.99; 95% CI 0.93-1.06). However, egg consumption >1 egg per day was associated with a decreased risk of coronary artery disease (HR 0.89; 95% CI 0.86-0.93; $p < 0.001$).

Comment: Eggs have gone in and out of favour over the years, confusing the general population as well as health practitioners. This led the NZ Nutrition Foundation to produce a lengthy white paper back in 2014, stating that one to two eggs a day was acceptable for healthy people. Yet uncertainty remained. Now we have this 2020 meta-analysis of 23 studies (finally?) concluding that more than one egg a day was actually beneficial for cardiac health. It will be interesting to see if this stance changes again in a few years.

Reference: *Am J Med.* 2021;134(1):76-83.e2

[Abstract](#)

Dr Christopher Tofield



Dr Tofield completed his medical training at St Bartholomew's and the Royal London Hospital in London. He has extensive experience in general practice, spent several years in clinical research, has published several medical papers, is clinical advisor to Bay of Plenty District Health Board and practices skin cancer medicine and surgery. Chris also has a background in medical writing and editing and while at medical school published a medical textbook on pharmacology. Chris is responsible for sourcing and short-listing national and international studies for GP Research Review. He also selects papers and provides commentary for the Natural Health section in GP Research Review.

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).